Drug Profile
EML 4156
Latest Information Update: 13 Nov 2003
Price :
$50
*
At a glance
- Originator Merck KGaA
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 13 Nov 2003 Discontinued - Phase-II for Type-2 diabetes mellitus in Europe (unspecified route)
- 15 May 2003 Phase-II clinical trials in Type-2 diabetes mellitus in Europe (unspecified route)
- 14 Apr 2003 Suspended - Phase-II for Type-2 diabetes mellitus in Europe (unspecified route)